Mode
Text Size
Log in / Sign up
Phase 2 N=15 Treatment

Pilot Evaluation of Platelet Rich Fibrin Matrix (PRFM) for the Correction of Nasolabial Folds

Nasolabial Folds

Enrolled (actual)
15
Serious AEs
0.0%
Results posted
Jul 2013
Primary outcome: Primary: Difference in Wrinkle Assessment Score, Between Pre-treatment and 12 Weeks Post-treatment. — 1.13 units on a scale

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
Platelet rich fibrin matrix (Biological)
Age
Adult, Older Adult · 25+ yrs
Sex
Female
Sponsor
The New York Eye & Ear Infirmary
Primary completion
Jun 2009

Outcome Measures

OutcomeResultp-value
PRIMARY
Difference in Wrinkle Assessment Score, Between Pre-treatment and 12 Weeks Post-treatment.
1.13
SECONDARY
Difference in Wrinkle Assessment Scores Between Pre-treatment and 1 Week
.65
SECONDARY
Difference in Wrinkle Assessment Score Between Pretreatment and 2 Weeks
.97
SECONDARY
Difference in Wrinkle Assessment Score Between Pretreatment and 6 Weeks
1.08

Summary

Platelets are a component of blood, which contain factors which can enhance wound healing. This study proposes to evaluate the clinical response of laugh lines treated with a concentrated preparation of the subject's own platelets injected into or under the skin by taking serial photographs of the subject's face over a 12 week period. Also, the same preparation will be injected into or under the skin of the arm near the elbows, and serial biopsies will be taken over a 12 week period.

Eligibility Criteria

Inclusion Criteria

  • healthy adults
  • aged 25- 75 years
  • with moderate to severe nasolabial folds

Exclusion Criteria

  • pregnant
  • allergy to local anesthetics
  • history of bleeding disorder
  • active infection at the treatment site
  • injectable filler in the nasolabial folds within past year
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00874094). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search